

Development of a Parenteral Formulation of NTS-Polyplex Nanoparticles for Clinical Purpose

María E. Aranda-Barradas ¹, Maripaz Márquez ^{2,3}, Liliana Quintanar ², Jaime Santoyo-Salazar ⁴, Armando J. Espadas-Álvarez ⁵, Daniel Martínez-Fong ^{1,5,t} and Elizabeth García-García ^{6,*}




Figure S1. Representative graphics of flow cytometry analysis of N1E-115 cells transfected with NTS-polyplex NPs in EF25 or in PF25.




Figure S2. Representative graphics of flow cytometry analysis of N1E-115 cells transfected with NTS-polyplex NPs formulated in PF25, lyophilized and reconstituted with water for injection.




Figure S3. Representative graphics of size distribution and zeta potential of freshly prepared NTS-polyplex NPs in PF25 or in EF25 and NPs formulated in PF25, lyophilized and reconstituted with water for injection.




Figure S4. Representative graphics of flow cytometry analysis of N1E-115 cells transfected with NTS-polyplex NPs formulated in PF25, lyophilized and reconstituted with water for injection after their storage for 6 months at 25 °C and 60% Relative Humidity.